MICRORNA SIGNATURES AS PREDICTIVE TOOLS FOR NEOADJUVANT CHEMOTHERAPY RESPONSES IN TNBC

Domas Štitilis1, 3, Adomas Vasiliauskas3, Linas Kunigėnas1, Monika Drobnienė1, 2, Eglė Strainienė1, 3, Kęstutis Sužiedėlis1, 2

1 National Cancer Institute

2 Life Sciences Center

3 Vilnius Gediminas Technical University

Breast cancer is the most common type of cancer among women. Triple-negative breast cancer (TNBC) is a subtype that is particularly aggressive and has limited treatment options, resulting in poor outcomes. This study focuses on the role of specific miRNAs in the progression of triple-negative breast cancer. Bioinformatics analysis of The Cancer Genome Atlas (TCGA) data identified 195 miRNAs that impact 57 genes associated with resistance to platinum-based therapies. Thus, we selected a subset of miRNAs and determined their expression levels through RT-PCR in triple-negative breast cancer (TNBC) patient samples, both before and after neoadjuvant therapy. Finally, the patients were stratified into a high-risk group and a low-risk group according to the median expression level of each miRNA.